Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07003191Active Not Recruiting

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Role: collaborator

NCT06565923Active Not Recruiting

Study on the Staging and Prognosis Model of Bladder Cancer

Role: collaborator

NCT05844371Phase 2Unknown

Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery

Role: lead

NCT05322330Phase 2Unknown

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Role: collaborator

NCT05253716Not ApplicableRecruiting

Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer

Role: collaborator

NCT05166733Unknown

A Retrospective Study of Reco Thrombectomy Stent for Intravascular Treatment of Acute Ischemic Stroke

Role: collaborator

All 6 trials loaded